109 tracked 13F filers disclose a position in AVTX as of the latest SEC 13F filings, a combined $638.0M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | STATE STREET CORP | $53.4M | 2.9M | ▲40× Added · +2.8M sh | Q2 2026 | |
| 2 | FMR LLC | $43.0M | 2.9M | ▲13× Added · +2.7M sh | Q1 2026 | |
| 3 | Avoro Capital Advisors LLC | $43.1M | 2.3M | ▲+65% Added · +923K sh | Q2 2026 | |
| 4 | T. Rowe Price Investment Management, Inc. | Withheld | 2.2M | ▲New +2.2M sh | Q1 2026 | |
| 5 | Nantahala Capital Management, LLC | $34.4M | 1.9M | ▲+51% Added · +627K sh | Q2 2026 | |
| 6 | Soleus Capital Management, L.P. | $30.6M | 1.7M | ▲+274% Added · +1.2M sh | Q2 2026 | |
| 7 | Caligan Partners LP | $24.4M | 1.6M | ▲+85% Added · +753K sh | Q1 2026 | |
| 8 | BVF INC/IL | $24.4M | 1.6M | ▲+20% Added · +278K sh | Q1 2026 | |
| 9 | BRAIDWELL LP | $30.1M | 1.6M | ▲New +1.6M sh | Q2 2026 | |
| 10 | Affinity Asset Advisors, LLC | $20.0M | 1.3M | ▲+28% Added · +290K sh | Q1 2026 | |
| 11 | UBS Group AG | $17.0M | 1.1M | ▲+139% Added · +664K sh | Q1 2026 | |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | $20.4M | 1.1M | ▲+550% Added · +935K sh | Q2 2026 | |
| 13 | Point72 Asset Management, L.P. | $13.7M | 916K | ▲+46% Added · +289K sh | Q1 2026 | |
| 14 | FARALLON CAPITAL MANAGEMENT, L.L.C. | $13.7M | 916K | ▲New +916K sh | Q1 2026 | |
| 15 | Trails Edge Capital Partners, LP | $16.5M | 892K | ▲New +892K sh | Q2 2026 | |
| 16 | ADAGE CAPITAL PARTNERS GP, L.L.C. | $12.8M | 854K | ▲+55% Added · +304K sh | Q1 2026 | |
| 17 | MILLENNIUM MANAGEMENT LLC | $12.5M | 835K | ▲+27% Added · +176K sh | Q1 2026 | |
| 18 | TCG Crossover Management, LLC | $11.0M | 738K | ▲+53% Added · +255K sh | Q1 2026 | |
| 19 | BALYASNY ASSET MANAGEMENT L.P. | $10.9M | 732K | ▲+67% Added · +292K sh | Q1 2026 | |
| 20 | VANGUARD CAPITAL MANAGEMENT LLC | $10.7M | 720K | →First observed position No prior filed position | Q1 2026 | |
| 21 | RA CAPITAL MANAGEMENT, L.P. | $9.9M | 663K | —Held | Q1 2026 | |
| 22 | BANK OF AMERICA CORP /DE/ | $9.6M | 643K | ▲+3.5% Added · +22K sh | Q1 2026 | |
| 23 | SILVERARC CAPITAL MANAGEMENT, LLC | $9.2M | 500K | ▲Added Added · +500K sh | Q2 2026 | |
| 24 | Commodore Capital LP | $7.2M | 483K | —Held | Q1 2026 | |
| 25 | ORBIMED ADVISORS LLC | $7.1M | 475K | ▼−60% Reduced · −712K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 28 funds opened a new position in AVTX and 25 added to an existing one, while 12 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| REVOLUTION MEDICINES INCRVMD | 50 funds | $3.7B |
| ELI LILLY & COLLY | 48 funds | $11.5B |
| CYTOKINETICS INCCYTK | 48 funds | $1.3B |
| INTUITIVE SURGICAL INCISRG | 47 funds | $5.2B |
| COGENT BIOSCIENCES INCCOGT | 47 funds | $935.9M |
| BOSTON SCIENTIFIC CORPBSX | 46 funds | $4.1B |
| NVIDIA CORPNVDA | 44 funds | $47.7B |
| MICROSOFT CORPMSFT | 44 funds | $27.7B |
| META PLATFORMS INC-CLASS AMETA | 44 funds | $15.5B |
| INSMED INCINSM | 44 funds | $2.0B |
| XENON PHARMACEUTICALS INCXENE | 44 funds | $1.3B |
| AMAZON.COM INCAMZN | 43 funds | $30.2B |
Ranked by how many of AVTX's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Aug 28, 2026 | Doyle Mittie | Chief Medical Officer | Sell (S) | 679 | $14K |
| Aug 18, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell (S) | 31K | $622K |
| Aug 17, 2026 | Doyle Mittie | Chief Medical Officer | Sell (S) | 1K | $20K |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell (S) | 4K | $75K |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell (S) | 38K | $753K |
| Aug 11, 2026 | Riley Jennifer | Chief Strategy Officer | Sell (S) | 3K | $52K |
| Aug 10, 2026 | Doyle Mittie | Chief Medical Officer | Sell (S) | 679 | $14K |
| Jul 27, 2026 | Doyle Mittie | Chief Medical Officer | Sell (S) | 1K | $20K |
| Jun 30, 2026 | Doyle Mittie | Chief Medical Officer | Sell (S) | 5K | $93K |
| Jun 23, 2026 | Doyle Mittie | Chief Medical Officer | Sell (S) | 1K | $26K |
| May 28, 2026 | Doyle Mittie | Chief Medical Officer | Sell (S) | 679 | $11K |
| May 15, 2026 | Doyle Mittie | Chief Medical Officer | Sell (S) | 3K | $56K |
Connected entities for AVTX
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/AVTX/capital-change-brief"
Use Arkolith's capital_change_brief for AVTX. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for AVTX. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.